During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...

The co-primary endpoints of overall response rate and overall survival were not met. The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ...

The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...